According to the information gathered by The Indian Express, at least 26 cases have been filed post November 30, 2017, and high courts have given relief to the firms in most of the cases by granting stay orders against any “coercive action” by NPPA.
If a drug molecule has seen a price reduction of less than 10 per cent under the current price “control methodology”, the Central government should exempt it from price control, according to a Niti Aayog proposal, which is currently under discussion.
India has told the United States it won’t abstain from capping prices for more medical devices, regardless of pressure to rethink its stance after price controls on heart stents and knee implants spoilt the market for some U.S. firms, sources familiar with the matter said.
While the National Pharmaceutical Pricing Authority (NPPA) revised the ceiling price on coronary stents on Monday, its Chairman Bhupendra Singh stated on Friday that that the price control is not the best option to achieve affordability. “If you ask me, I don’t consider that price control is the best option to achieve affordability.